Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia

International Journal of Clinical Pharmacy

Volumn 33, Issue 1, 2011, Pages 58-60

  Bauters, T ^a   Mondelaers, V ^a   Robays, H ^a   De Wilde, H ^a   Benoit, Y ^a   De Moerloose, B ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Clinical pharmacy; Hemolytic anemia; Methemoglobinemia; Pancreatitis; Pediatric hematooncology; Rasburicase

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISOLONE; RASBURICASE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CAUSAL ATTRIBUTION; CHILD; CHILD CARE; CHILDHOOD LEUKEMIA; CYANOSIS; DISEASE SEVERITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; METHEMOGLOBINEMIA; OXYGEN THERAPY; PATIENT MONITORING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION;

ANEMIA, HEMOLYTIC; CHILD; HUMANS; MALE; METHEMOGLOBINEMIA; PANCREATITIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 79960031897     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-011-9484-3     Document Type: Article

References (13)

1. Ueng S. Rasburicase (Elitek): A novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent). 2005;18(3):275-9.
2. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001;19(3):697-704. (Pubitemid 32119083)
3. Cairo MS. Prevention and treatment of hyperuricemia in hematological malignancies. Clin Lymphoma. 2002; Suppl 1:S26-31.
4. de Bont JM, Pieters R. Management of hyperuricemia with rasburicase review. Nucleosides Nucleotides Nucleic Acids. 2004; 23(8-9):1431-40. (Pubitemid 39625938)
5. Browning LA, Kruse J. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother. 2005;39(11):1932-5. (Pubitemid 41527709)
6. Maher JF, Rath CE, Schreiner GE. Hyperuricemia complicating leukemia: Treatment with allopurinol and dialysis. Arch Intern Med. 1969;123(2):198-200.
7. E-Compendium. Scientific Leaflet Fasturtec (in Flemish). Available from: Http://www.ecompendium.be/. Accessed on 12 May 2010.
8. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97(10): 2998-3003.
9. Kizer N, Martinez E, Powell M. Report of two cases of rasburicase-induced methemoglobinemia. Leuk Lymphoma. 2006;47(12): 2648-50. (Pubitemid 44932657)
10. Identifying Adverse Drug Reactions. Available from http:// qmweb.dads.state.tx.us/MedSim/Naranjo.htm. Accessed on 14 Apr 2010.
11. Borinstein SC, Xu M, Hawkins DS. Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia. Pediatr Blood Cancer. 2008;50(1):189. (Pubitemid 350234303)
12. Bhat P, Sisler I, Collier AB 3rd. Exchange transfusion as treatment for rasburicase induced methemoglobinemia in a glucose-6-phosphate dehydrogenase deficient patient. Pediatr Blood Cancer. 2008;51(4):568.
13. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-9.